PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1423556
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1423556
Gabapentin Market Forecasts to 2030 - Global Analysis By Product (Tablet, Capsule and Other Products), Type (Generic, Branded and Other Types), Route of Administration, Mode of Purchase, Application, End User and By Geography
According to Stratistics MRC, the Global Gabapentin Market is accounted for $2,171.52 million in 2023 and is expected to reach $3,567.61 million by 2030 growing at a CAGR of 7.4% during the forecast period. Gabapentin is a pharmaceutical compound used primarily as an anticonvulsant and to alleviate neuropathic pain which mimic the neurotransmitter gamma-aminobutyric acid (GABA). It is approved by the U.S. Food and Drug Administration (FDA), and is employed in the treatment of various medical conditions, including epilepsy, postherpetic neuralgia, and restless legs syndrome. The drug's versatility in addressing neurological disorders and chronic pain has made it a valuable asset in modern medicine.
According to a report, gabapentin ranks sixth in prescribed medication in the United States in 2020. Nearly, 57 million prescriptions were written for the drug in the country in 2020.
Market Dynamics:
Driver:
Increase in awareness
Healthcare professionals and patients are becoming more informed about the drug's efficacy in managing various neurological disorders and neuropathic pain conditions. Physicians are increasingly prescribing Gabapentin based on a deeper understanding of its mechanisms of action and the diverse range of conditions it can effectively address. In addition, the evolving landscape of patient-centered healthcare encourages informed decision-making, making awareness a crucial factor in driving this market.
Restraint:
Misuse and abuse
Gabapentin misuse can involve taking higher doses than prescribed, using it without a prescription, or combining it with other substances to intensify the desired effects. Abuse of gabapentin can result in various adverse effects, including dizziness, sedation, impaired coordination, blurred vision, and cognitive difficulties. Furthermore, abrupt discontinuation of gabapentin after prolonged misuse or abuse can result in withdrawal symptoms such as anxiety, insomnia, and restlessness, significantly hampering this market expansion.
Opportunity:
Telehealth expansion
The expansion of telehealth services serves healthcare and positively impacts the accessibility of this medication by transforming easy delivery for individuals requiring gabapentin for neurological disorders and neuropathic pain. Telehealth allows healthcare providers to conduct remote consultations, prescribe medications, and monitor patients' conditions from a distance. Further, telehealth enables healthcare professionals to monitor patients remotely, address concerns promptly, and optimize medication management, which is propelling this market
Threat:
Side effects and tolerance
The prevalence of side effects poses challenges for healthcare providers in balancing the therapeutic benefits of Gabapentin with its potential drawbacks. Patient-specific factors, such as age, underlying health conditions, and concurrent medications, can influence the likelihood and severity of side effects. Moreover, the presence of side effects may necessitate additional medical interventions, contributing to healthcare costs and resource utilization and thereby hindering market growth.
Covid-19 Impact
The COVID-19 pandemic has had several negative impacts on the Gabapentin market. Supply chain disruptions, lockdown measures, and shifts in healthcare priorities have collectively contributed to challenges in the production, distribution, and consumption of gabapentin. Economic uncertainties and financial strains on healthcare systems have prompted cost-cutting measures, potentially influencing the affordability of Gabapentin. Moreover, reduced patient visits to healthcare providers may have led to a decline in new prescriptions and refills, affecting overall market demand.
The capsule segment is expected to be the largest during the forecast period
The capsule segment is estimated to hold the largest share. These are pharmaceutical products widely prescribed for neurological disorders and neuropathic pain that are efficient in managing conditions like epilepsy, postherpetic neuralgia, and diabetic neuropathy. Factors such as research and development initiatives, regulatory approvals, and strategic collaborations influence market dynamics. Furthermore, a focus on innovation, safety, and accessibility continues to be a vital contributor to the broader pharmaceutical market, driving this segment's growth.
The parenteral segment is expected to have the highest CAGR during the forecast period
The parenteral segment is anticipated to have highest CAGR during the forecast period due to distinct advantages, particularly in situations where oral intake may be challenging, such as for patients experiencing nausea, vomiting, or those with difficulty swallowing. This mode of delivery enhances treatment compliance and ensures patients receive the prescribed dosage accurately. Additionally, for individuals requiring rapid onset of action or precise dosage control, parenteral formulations of gabapentin provide an effective alternative, boosting this segment's expansion.
Region with largest share:
North America commanded the largest market share during the extrapolated period owing to its significant presence in the pharmaceutical landscape, addressing neurological disorders and neuropathic pain. Key markets such as Pfizer Inc., Teva Pharmaceuticals Ltd., Glenmark Pharmaceuticals Limited, and Cipla USA Inc. have become cornerstones in the management of conditions like epilepsy, postherpetic neuralgia, and diabetic neuropathy. Furthermore, regulatory oversight from agencies like the U.S. Food and Drug Administration (FDA) and Health Canada ensures compliance with safety standards and effective distribution in this region.
Region with highest CAGR:
Europe is expected to witness highest CAGR over the projection period, owing to its efficacy in managing conditions like epilepsy, postherpetic neuralgia, and diabetic neuropathy. Pharmaceutical companies engage in manufacturing and marketing activities to meet the increasing demand for Gabapentin, aiming to provide effective solutions for individuals grappling with neurological conditions in Europe. In addition, factors such as the rising prevalence of neurological disorders, an aging population, and an increased awareness of chronic pain management are boosting this region's expansion.
Key players in the market
Some of the key players in the Gabapentin Market include Amneal Pharmaceuticals LLC., Intas Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd, Marksans Pharma, Novartis AG, Alkem Labs, Jiangsu Nhwa Pharmaceutical Co., Ltd, Aurobindo Pharma, Apotex Inc, Viatris Inc, Arbor Pharmaceuticals, LLC, Pfizer Inc, Teva Pharmaceuticals Ltd, Glenmark Pharmaceuticals Limited, Ascend Laboratories, LLC and Cipla USA, Inc.
Key Developments:
In December 2023, Pfizer Inc. announced the successful completion of its acquisition of Seagen Inc, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines.
In October 2023, Zydus Lifesciences Company and Sun Pharmaceutical Industries Limited announced that both companies have entered into a licensing agreement to co-market an innovative drug, Desidustat in India.
In January 2023, Sun Pharmaceutical Industries Limited and Concert Pharmaceuticals, Inc. announced that they have executed a definitive agreement under which Sun Pharma will acquire all outstanding shares of Concert through a tender offer for an upfront payment in equity value.
Products Covered:
- Tablet
- Capsule
- Other Products
Types Covered:
- Generic
- Branded
- Other Types
Route of Administrations Covered:
- Parenteral
- Oral
- Intravenous
- Other Route of Administrations
Mode of Purchase Covered:
- Prescription
- Over the Counter(OTC)
- Retail
Applications Covered:
- Neuropathic Pain
- Epilepsy
- Restless Legs Syndrome
- Other Applications
End Users Covered:
- Online Pharmacies
- Hospital Pharmacy
- Other End Users
Regions Covered:
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
- South America
- Argentina
- Brazil
- Chile
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
- Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
- Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
- Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
- 2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions
3 Market Trend Analysis
- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Product Analysis
- 3.7 Application Analysis
- 3.8 End User Analysis
- 3.9 Emerging Markets
- 3.10 Impact of Covid-19
4 Porters Five Force Analysis
- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry
5 Global Gabapentin Market, By Product
- 5.1 Introduction
- 5.2 Tablet
- 5.3 Capsule
- 5.4 Other Products
6 Global Gabapentin Market, By Type
- 6.1 Introduction
- 6.2 Generic
- 6.3 Branded
- 6.4 Other Types
7 Global Gabapentin Market, By Route of Administration
- 7.1 Introduction
- 7.2 Parenteral
- 7.3 Oral
- 7.4 Intravenous
- 7.5 Other Route of Administrations
8 Global Gabapentin Market, By Mode of Purchase
- 8.1 Introduction
- 8.2 Prescription
- 8.3 Over the Counter (OTC)
- 8.4 Retail
9 Global Gabapentin Market, By Application
- 9.1 Introduction
- 9.2 Neuropathic Pain
- 9.3 Epilepsy
- 9.4 Restless Legs Syndrome
- 9.5 Other Applications
10 Global Gabapentin Market, By End User
- 10.1 Introduction
- 10.2 Online Pharmacies
- 10.3 Hospital Pharmacy
- 10.4 Other End Users
11 Global Gabapentin Market, By Geography
- 11.1 Introduction
- 11.2 North America
- 11.2.1 US
- 11.2.2 Canada
- 11.2.3 Mexico
- 11.3 Europe
- 11.3.1 Germany
- 11.3.2 UK
- 11.3.3 Italy
- 11.3.4 France
- 11.3.5 Spain
- 11.3.6 Rest of Europe
- 11.4 Asia Pacific
- 11.4.1 Japan
- 11.4.2 China
- 11.4.3 India
- 11.4.4 Australia
- 11.4.5 New Zealand
- 11.4.6 South Korea
- 11.4.7 Rest of Asia Pacific
- 11.5 South America
- 11.5.1 Argentina
- 11.5.2 Brazil
- 11.5.3 Chile
- 11.5.4 Rest of South America
- 11.6 Middle East & Africa
- 11.6.1 Saudi Arabia
- 11.6.2 UAE
- 11.6.3 Qatar
- 11.6.4 South Africa
- 11.6.5 Rest of Middle East & Africa
12 Key Developments
- 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 12.2 Acquisitions & Mergers
- 12.3 New Product Launch
- 12.4 Expansions
- 12.5 Other Key Strategies
13 Company Profiling
- 13.1 Amneal Pharmaceuticals LLC.
- 13.2 Intas Pharmaceuticals Ltd.
- 13.3 Sun Pharmaceutical Industries Ltd
- 13.4 Marksans Pharma
- 13.5 Novartis AG
- 13.6 Alkem Labs
- 13.7 Jiangsu Nhwa Pharmaceutical Co., Ltd
- 13.8 Aurobindo Pharma
- 13.9 Apotex Inc
- 13.10 Viatris Inc
- 13.11 Arbor Pharmaceuticals, LLC
- 13.12 Pfizer Inc
- 13.13 Teva Pharmaceuticals Ltd
- 13.14 Glenmark Pharmaceuticals Limited
- 13.15 Ascend Laboratories, LLC
- 13.16 Cipla USA, Inc.
List of Tables
- Table 1 Global Gabapentin Market Outlook, By Region (2021-2030) ($MN)
- Table 2 Global Gabapentin Market Outlook, By Product (2021-2030) ($MN)
- Table 3 Global Gabapentin Market Outlook, By Tablet (2021-2030) ($MN)
- Table 4 Global Gabapentin Market Outlook, By Capsule (2021-2030) ($MN)
- Table 5 Global Gabapentin Market Outlook, By Other Products (2021-2030) ($MN)
- Table 6 Global Gabapentin Market Outlook, By Type (2021-2030) ($MN)
- Table 7 Global Gabapentin Market Outlook, By Generic (2021-2030) ($MN)
- Table 8 Global Gabapentin Market Outlook, By Branded (2021-2030) ($MN)
- Table 9 Global Gabapentin Market Outlook, By Other Types (2021-2030) ($MN)
- Table 10 Global Gabapentin Market Outlook, By Route of Administration (2021-2030) ($MN)
- Table 11 Global Gabapentin Market Outlook, By Parenteral (2021-2030) ($MN)
- Table 12 Global Gabapentin Market Outlook, By Oral (2021-2030) ($MN)
- Table 13 Global Gabapentin Market Outlook, By Intravenous (2021-2030) ($MN)
- Table 14 Global Gabapentin Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
- Table 15 Global Gabapentin Market Outlook, By Mode of Purchase (2021-2030) ($MN)
- Table 16 Global Gabapentin Market Outlook, By Prescription (2021-2030) ($MN)
- Table 17 Global Gabapentin Market Outlook, By Over the Counter (OTC) (2021-2030) ($MN)
- Table 18 Global Gabapentin Market Outlook, By Retail (2021-2030) ($MN)
- Table 19 Global Gabapentin Market Outlook, By Application (2021-2030) ($MN)
- Table 20 Global Gabapentin Market Outlook, By Neuropathic Pain (2021-2030) ($MN)
- Table 21 Global Gabapentin Market Outlook, By Epilepsy (2021-2030) ($MN)
- Table 22 Global Gabapentin Market Outlook, By Restless Legs Syndrome (2021-2030) ($MN)
- Table 23 Global Gabapentin Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 24 Global Gabapentin Market Outlook, By End User (2021-2030) ($MN)
- Table 25 Global Gabapentin Market Outlook, By Online Pharmacies (2021-2030) ($MN)
- Table 26 Global Gabapentin Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
- Table 27 Global Gabapentin Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 28 North America Gabapentin Market Outlook, By Country (2021-2030) ($MN)
- Table 29 North America Gabapentin Market Outlook, By Product (2021-2030) ($MN)
- Table 30 North America Gabapentin Market Outlook, By Tablet (2021-2030) ($MN)
- Table 31 North America Gabapentin Market Outlook, By Capsule (2021-2030) ($MN)
- Table 32 North America Gabapentin Market Outlook, By Other Products (2021-2030) ($MN)
- Table 33 North America Gabapentin Market Outlook, By Type (2021-2030) ($MN)
- Table 34 North America Gabapentin Market Outlook, By Generic (2021-2030) ($MN)
- Table 35 North America Gabapentin Market Outlook, By Branded (2021-2030) ($MN)
- Table 36 North America Gabapentin Market Outlook, By Other Types (2021-2030) ($MN)
- Table 37 North America Gabapentin Market Outlook, By Route of Administration (2021-2030) ($MN)
- Table 38 North America Gabapentin Market Outlook, By Parenteral (2021-2030) ($MN)
- Table 39 North America Gabapentin Market Outlook, By Oral (2021-2030) ($MN)
- Table 40 North America Gabapentin Market Outlook, By Intravenous (2021-2030) ($MN)
- Table 41 North America Gabapentin Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
- Table 42 North America Gabapentin Market Outlook, By Mode of Purchase (2021-2030) ($MN)
- Table 43 North America Gabapentin Market Outlook, By Prescription (2021-2030) ($MN)
- Table 44 North America Gabapentin Market Outlook, By Over the Counter (OTC) (2021-2030) ($MN)
- Table 45 North America Gabapentin Market Outlook, By Retail (2021-2030) ($MN)
- Table 46 North America Gabapentin Market Outlook, By Application (2021-2030) ($MN)
- Table 47 North America Gabapentin Market Outlook, By Neuropathic Pain (2021-2030) ($MN)
- Table 48 North America Gabapentin Market Outlook, By Epilepsy (2021-2030) ($MN)
- Table 49 North America Gabapentin Market Outlook, By Restless Legs Syndrome (2021-2030) ($MN)
- Table 50 North America Gabapentin Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 51 North America Gabapentin Market Outlook, By End User (2021-2030) ($MN)
- Table 52 North America Gabapentin Market Outlook, By Online Pharmacies (2021-2030) ($MN)
- Table 53 North America Gabapentin Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
- Table 54 North America Gabapentin Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 55 Europe Gabapentin Market Outlook, By Country (2021-2030) ($MN)
- Table 56 Europe Gabapentin Market Outlook, By Product (2021-2030) ($MN)
- Table 57 Europe Gabapentin Market Outlook, By Tablet (2021-2030) ($MN)
- Table 58 Europe Gabapentin Market Outlook, By Capsule (2021-2030) ($MN)
- Table 59 Europe Gabapentin Market Outlook, By Other Products (2021-2030) ($MN)
- Table 60 Europe Gabapentin Market Outlook, By Type (2021-2030) ($MN)
- Table 61 Europe Gabapentin Market Outlook, By Generic (2021-2030) ($MN)
- Table 62 Europe Gabapentin Market Outlook, By Branded (2021-2030) ($MN)
- Table 63 Europe Gabapentin Market Outlook, By Other Types (2021-2030) ($MN)
- Table 64 Europe Gabapentin Market Outlook, By Route of Administration (2021-2030) ($MN)
- Table 65 Europe Gabapentin Market Outlook, By Parenteral (2021-2030) ($MN)
- Table 66 Europe Gabapentin Market Outlook, By Oral (2021-2030) ($MN)
- Table 67 Europe Gabapentin Market Outlook, By Intravenous (2021-2030) ($MN)
- Table 68 Europe Gabapentin Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
- Table 69 Europe Gabapentin Market Outlook, By Mode of Purchase (2021-2030) ($MN)
- Table 70 Europe Gabapentin Market Outlook, By Prescription (2021-2030) ($MN)
- Table 71 Europe Gabapentin Market Outlook, By Over the Counter (OTC) (2021-2030) ($MN)
- Table 72 Europe Gabapentin Market Outlook, By Retail (2021-2030) ($MN)
- Table 73 Europe Gabapentin Market Outlook, By Application (2021-2030) ($MN)
- Table 74 Europe Gabapentin Market Outlook, By Neuropathic Pain (2021-2030) ($MN)
- Table 75 Europe Gabapentin Market Outlook, By Epilepsy (2021-2030) ($MN)
- Table 76 Europe Gabapentin Market Outlook, By Restless Legs Syndrome (2021-2030) ($MN)
- Table 77 Europe Gabapentin Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 78 Europe Gabapentin Market Outlook, By End User (2021-2030) ($MN)
- Table 79 Europe Gabapentin Market Outlook, By Online Pharmacies (2021-2030) ($MN)
- Table 80 Europe Gabapentin Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
- Table 81 Europe Gabapentin Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 82 Asia Pacific Gabapentin Market Outlook, By Country (2021-2030) ($MN)
- Table 83 Asia Pacific Gabapentin Market Outlook, By Product (2021-2030) ($MN)
- Table 84 Asia Pacific Gabapentin Market Outlook, By Tablet (2021-2030) ($MN)
- Table 85 Asia Pacific Gabapentin Market Outlook, By Capsule (2021-2030) ($MN)
- Table 86 Asia Pacific Gabapentin Market Outlook, By Other Products (2021-2030) ($MN)
- Table 87 Asia Pacific Gabapentin Market Outlook, By Type (2021-2030) ($MN)
- Table 88 Asia Pacific Gabapentin Market Outlook, By Generic (2021-2030) ($MN)
- Table 89 Asia Pacific Gabapentin Market Outlook, By Branded (2021-2030) ($MN)
- Table 90 Asia Pacific Gabapentin Market Outlook, By Other Types (2021-2030) ($MN)
- Table 91 Asia Pacific Gabapentin Market Outlook, By Route of Administration (2021-2030) ($MN)
- Table 92 Asia Pacific Gabapentin Market Outlook, By Parenteral (2021-2030) ($MN)
- Table 93 Asia Pacific Gabapentin Market Outlook, By Oral (2021-2030) ($MN)
- Table 94 Asia Pacific Gabapentin Market Outlook, By Intravenous (2021-2030) ($MN)
- Table 95 Asia Pacific Gabapentin Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
- Table 96 Asia Pacific Gabapentin Market Outlook, By Mode of Purchase (2021-2030) ($MN)
- Table 97 Asia Pacific Gabapentin Market Outlook, By Prescription (2021-2030) ($MN)
- Table 98 Asia Pacific Gabapentin Market Outlook, By Over the Counter (OTC) (2021-2030) ($MN)
- Table 99 Asia Pacific Gabapentin Market Outlook, By Retail (2021-2030) ($MN)
- Table 100 Asia Pacific Gabapentin Market Outlook, By Application (2021-2030) ($MN)
- Table 101 Asia Pacific Gabapentin Market Outlook, By Neuropathic Pain (2021-2030) ($MN)
- Table 102 Asia Pacific Gabapentin Market Outlook, By Epilepsy (2021-2030) ($MN)
- Table 103 Asia Pacific Gabapentin Market Outlook, By Restless Legs Syndrome (2021-2030) ($MN)
- Table 104 Asia Pacific Gabapentin Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 105 Asia Pacific Gabapentin Market Outlook, By End User (2021-2030) ($MN)
- Table 106 Asia Pacific Gabapentin Market Outlook, By Online Pharmacies (2021-2030) ($MN)
- Table 107 Asia Pacific Gabapentin Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
- Table 108 Asia Pacific Gabapentin Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 109 South America Gabapentin Market Outlook, By Country (2021-2030) ($MN)
- Table 110 South America Gabapentin Market Outlook, By Product (2021-2030) ($MN)
- Table 111 South America Gabapentin Market Outlook, By Tablet (2021-2030) ($MN)
- Table 112 South America Gabapentin Market Outlook, By Capsule (2021-2030) ($MN)
- Table 113 South America Gabapentin Market Outlook, By Other Products (2021-2030) ($MN)
- Table 114 South America Gabapentin Market Outlook, By Type (2021-2030) ($MN)
- Table 115 South America Gabapentin Market Outlook, By Generic (2021-2030) ($MN)
- Table 116 South America Gabapentin Market Outlook, By Branded (2021-2030) ($MN)
- Table 117 South America Gabapentin Market Outlook, By Other Types (2021-2030) ($MN)
- Table 118 South America Gabapentin Market Outlook, By Route of Administration (2021-2030) ($MN)
- Table 119 South America Gabapentin Market Outlook, By Parenteral (2021-2030) ($MN)
- Table 120 South America Gabapentin Market Outlook, By Oral (2021-2030) ($MN)
- Table 121 South America Gabapentin Market Outlook, By Intravenous (2021-2030) ($MN)
- Table 122 South America Gabapentin Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
- Table 123 South America Gabapentin Market Outlook, By Mode of Purchase (2021-2030) ($MN)
- Table 124 South America Gabapentin Market Outlook, By Prescription (2021-2030) ($MN)
- Table 125 South America Gabapentin Market Outlook, By Over the Counter (OTC) (2021-2030) ($MN)
- Table 126 South America Gabapentin Market Outlook, By Retail (2021-2030) ($MN)
- Table 127 South America Gabapentin Market Outlook, By Application (2021-2030) ($MN)
- Table 128 South America Gabapentin Market Outlook, By Neuropathic Pain (2021-2030) ($MN)
- Table 129 South America Gabapentin Market Outlook, By Epilepsy (2021-2030) ($MN)
- Table 130 South America Gabapentin Market Outlook, By Restless Legs Syndrome (2021-2030) ($MN)
- Table 131 South America Gabapentin Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 132 South America Gabapentin Market Outlook, By End User (2021-2030) ($MN)
- Table 133 South America Gabapentin Market Outlook, By Online Pharmacies (2021-2030) ($MN)
- Table 134 South America Gabapentin Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
- Table 135 South America Gabapentin Market Outlook, By Other End Users (2021-2030) ($MN)
- Table 136 Middle East & Africa Gabapentin Market Outlook, By Country (2021-2030) ($MN)
- Table 137 Middle East & Africa Gabapentin Market Outlook, By Product (2021-2030) ($MN)
- Table 138 Middle East & Africa Gabapentin Market Outlook, By Tablet (2021-2030) ($MN)
- Table 139 Middle East & Africa Gabapentin Market Outlook, By Capsule (2021-2030) ($MN)
- Table 140 Middle East & Africa Gabapentin Market Outlook, By Other Products (2021-2030) ($MN)
- Table 141 Middle East & Africa Gabapentin Market Outlook, By Type (2021-2030) ($MN)
- Table 142 Middle East & Africa Gabapentin Market Outlook, By Generic (2021-2030) ($MN)
- Table 143 Middle East & Africa Gabapentin Market Outlook, By Branded (2021-2030) ($MN)
- Table 144 Middle East & Africa Gabapentin Market Outlook, By Other Types (2021-2030) ($MN)
- Table 145 Middle East & Africa Gabapentin Market Outlook, By Route of Administration (2021-2030) ($MN)
- Table 146 Middle East & Africa Gabapentin Market Outlook, By Parenteral (2021-2030) ($MN)
- Table 147 Middle East & Africa Gabapentin Market Outlook, By Oral (2021-2030) ($MN)
- Table 148 Middle East & Africa Gabapentin Market Outlook, By Intravenous (2021-2030) ($MN)
- Table 149 Middle East & Africa Gabapentin Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
- Table 150 Middle East & Africa Gabapentin Market Outlook, By Mode of Purchase (2021-2030) ($MN)
- Table 151 Middle East & Africa Gabapentin Market Outlook, By Prescription (2021-2030) ($MN)
- Table 152 Middle East & Africa Gabapentin Market Outlook, By Over the Counter (OTC) (2021-2030) ($MN)
- Table 153 Middle East & Africa Gabapentin Market Outlook, By Retail (2021-2030) ($MN)
- Table 154 Middle East & Africa Gabapentin Market Outlook, By Application (2021-2030) ($MN)
- Table 155 Middle East & Africa Gabapentin Market Outlook, By Neuropathic Pain (2021-2030) ($MN)
- Table 156 Middle East & Africa Gabapentin Market Outlook, By Epilepsy (2021-2030) ($MN)
- Table 157 Middle East & Africa Gabapentin Market Outlook, By Restless Legs Syndrome (2021-2030) ($MN)
- Table 158 Middle East & Africa Gabapentin Market Outlook, By Other Applications (2021-2030) ($MN)
- Table 159 Middle East & Africa Gabapentin Market Outlook, By End User (2021-2030) ($MN)
- Table 160 Middle East & Africa Gabapentin Market Outlook, By Online Pharmacies (2021-2030) ($MN)
- Table 161 Middle East & Africa Gabapentin Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
- Table 162 Middle East & Africa Gabapentin Market Outlook, By Other End Users (2021-2030) ($MN)
